Nanoliposomes Co-Encapsulating CT Imaging Contrast Agent and Photosensitizer for Enhanced, Imaging Guided Photodynamic Therapy of Cancer.,Theranostics

当前位置： X-MOL 学术 › Theranostics › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Nanoliposomes Co-Encapsulating CT Imaging Contrast Agent and Photosensitizer for Enhanced, Imaging Guided Photodynamic Therapy of Cancer.
Theranostics ( IF 12.4 ) Pub Date : 2019-01-01 , DOI: 10.7150/thno.31079
Hao Xu _{1,

2} , Tymish Y Ohulchanskyy ₁ , Artem Yakovliev ₁ , Roman Zinyuk ₁ , Jun Song ₁ , Liwei Liu ₁ , Junle Qu ₁ , Zhen Yuan ₂

Affiliation

Fluorescence (FL) and X-ray computed tomography (CT) imaging-guided photodynamic therapy (PDT) can provide a powerful theranostic tool to visualize, monitor, and treat cancer and other diseases with enhanced accuracy and efficacy. Methods: In this study, clinically approved iodinated CT imaging contrast agent (CTIA) iodixanol and commercially available photosensitizer (PS) meso-tetrakis (4-sulphonatophenyl) porphine (TPPS4) were co-encapsulated in biocompatible PEGylated nanoliposomes (NL) for enhanced anticancer PDT guided by bimodal (FL and CT) imaging. Results: The NL co-encapsulation of iodixanol and TPPS4 (LIT) lead to an increase in singlet oxygen generation by PS via the intraparticle heavy-atom (iodine) effect on PS molecules, as it was confirmed by both direct and indirect measurements of singlet oxygen production. The confocal imaging and PDT of cancer cells were performed in vitro, exhibiting the cellular uptake of TPPS4 formulations and enhanced PDT efficacy of LIT. Meanwhile, bimodal (FL and CT) imaging was also conducted with tumor-bearing mice and the imaging results manifested high-efficient accumulation and retention of LIT in tumors. Moreover, PDT of tumor in vivo was shown to be drastically more efficient with LIT than with other formulations of TPPS4. Conclusion: This study demonstrated that LIT can serve as a highly efficient theranostic nanoplatform for enhanced anticancer PDT guided by bimodal (FL and CT) imaging.

中文翻译：

纳米脂质体共封装 CT 成像造影剂和光敏剂，用于增强成像引导的癌症光动力治疗。

荧光 (FL) 和 X 射线计算机断层扫描 (CT) 成像引导光动力治疗 (PDT) 可以提供强大的治疗诊断工具，以提高准确性和功效来可视化、监测和治疗癌症和其他疾病。方法：在本研究中，将临床批准的碘化 CT 成像造影剂 (CTIA) 碘克沙醇和市售光敏剂 (PS) 内消旋四（4-磺基苯基）卟啉 (TPPS4) 共同封装在生物相容性聚乙二醇化纳米脂质体 (NL) 中，以增强抗癌作用由双模态（FL 和 CT）成像引导的 PDT。结果：碘克沙醇和 TPPS4 (LIT) 的 NL 共封装导致 PS 通过粒子内重原子（碘）对 PS 分子的影响增加单线态氧的产生，单线态的直接和间接测量证实了这一点氧气的产生。癌细胞的共聚焦成像和 PDT 在体外进行，显示了 TPPS4 制剂的细胞摄取和 LIT 增强的 PDT 功效。同时，还对荷瘤小鼠进行了双模态（FL和CT）成像，成像结果显示LIT在肿瘤中高效积累和保留。此外，与其他 TPPS4 制剂相比，LIT 对体内肿瘤的 PDT 效果显着提高。结论：本研究表明，LIT 可以作为一种高效的治疗诊断纳米平台，用于双模态（FL 和 CT）成像引导的增强抗癌 PDT。

更新日期：2019-01-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南